PlainPharmaWatch

CMS Open Payments · Tool

Guerbet LLC vs Idorsia Pharmaceuticals US Inc

Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.

A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.

Compare Different Companies

vs

Relationship comparison

Which recorded payment profile is more concentrated?

Guerbet LLC has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 722, versus 75 for the other company. Its single largest recorded recipient represents 0.2% of that company's General Payments recipient total.

HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.

Guerbet LLC
HHI 722 · top recipient 0.2%
Ranked #1,160 of 1,838 companies by HHI
Idorsia Pharmaceuticals US Inc
HHI 75 · top recipient 0.0%
Ranked #1,726 of 1,838 companies by HHI

Payment Overview

Company A

Guerbet LLC

Total Payments
$1.8M
% of Industry
0.0%
Transactions
468
Avg per Transaction
$3.9K
Recipients
368
Avg per Recipient
$5.0K
Payment Types
4
Top Payment Type
Consulting Fee
Total Payments
$1.8M
% of Industry
0.0%
Transactions
21,025
Avg per Transaction
$87.00
Recipients
20,929
Avg per Recipient
$87.40
Payment Types
6
Top Payment Type
Compensation for Services Other Than Consulting

Highlighted values indicate the higher figure for each metric.

Total payments compared

Guerbet LLC vs Idorsia Pharmaceuticals US Inc - total reported payments in CMS Open Payments PY2024

Guerbet LLC$1.8MIdorsia Pharmaceuticals US…$1.8M

Payment Types Breakdown

Guerbet LLC

Consulting Fee $401.1K

21.9%

Travel and Lodging $132.6K

7.2%

Food and Beverage $29.3K

1.6%

Compensation for Services Other Than Consulting $26.2K

1.4%

Idorsia Pharmaceuticals US Inc

Compensation for Services Other Than Consulting $660.3K

36.1%

Food and Beverage $431.3K

23.6%

Travel and Lodging $86.8K

4.7%

Consulting Fee $24.8K

1.4%

Grant $5.0K

0.3%

Education $2.8K

0.2%

Top 5 General-Payment Recipients

This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.

Guerbet LLC

  1. 1

    LAWRENCE N TANENBAUM

    $101,639.24 · 23 txns

  2. 2

    JEFFREY H MAKI

    $86,532.38 · 21 txns

  3. 3

    LAURIE A LOEVNER

    $45,064.49 · 7 txns

  4. 4

    BACHIR TAOULI

    $30,631.39 · 11 txns

  5. 5

    DONNA ROBERTS

    $27,608.93 · 13 txns

Idorsia Pharmaceuticals US Inc

  1. 1

    DOMINGO RODRIGUEZ-CUE

    $37,458.82 · 67 txns

  2. 2

    ALON AVIDAN

    $34,238.11 · 35 txns

  3. 3

    GREG L FRIEDMAN

    $31,932.91 · 88 txns

  4. 4

    VIKAS JAIN

    $30,478.21 · 34 txns

  5. 5

    MICHAEL WEBER

    $28,018.79 · 11 txns

Summary Comparison

Metric Guerbet LLC Idorsia Pharmaceuticals US Inc
Total Payments $1.8M $1.8M
% of Industry Total 0.0% 0.0%
Transaction Count 468 21,025
Avg per Transaction $3.9K $87.00
Recipient Count 368 20,929
Avg per Recipient $5.0K $87.40
Payment Type Count 4 6
Top Payment Type Consulting Fee Compensation for Services Other Than Consulting

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.